Compounds > cyclomarin a
Page last updated: 2024-11-12

cyclomarin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclomarin A: extract of Streptomyces [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10772429
CHEBI ID182606
MeSH IDM0429877

Synonyms (5)

Synonym
cyclomarin a
CHEBI:182606
(3s,6s,9s,12s,15s,18s,21s)-21-[(2r)-3-hydroxy-2-methylpropyl]-3-[(r)-hydroxy-[1-[2-[(2r)-oxiran-2-yl]propan-2-yl]indol-3-yl]methyl]-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9-(2-methylpropyl)-12-propan-2-yl-1,4,7,10
169062-92-4
DTXSID601347033
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
azamacrocycleA cyclic macromolecule containing one or more nitrogen atoms in place of carbon either as the divalent group NH for the group CH2 or a single trivalent nitrogen atom for the group CH.
keratan 6'-sulfateA keratan sulfate with random sulfation at the 6'-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's10 (76.92)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.92 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		2.1710arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
surfactin peptide
surfactin peptide: antineoplastic product isolated from Bacillus sp.		2.0110
viscosin
viscosin: cyclic peptide lactone with alternating D and L amino acids; found in Pseudomonas viscosa; amino acid sequence given in first source		2.0110
phospho-l-arginine
phospho-L-arginine: inhibits pyruvate kinase. N(omega)-phospho-L-arginine : An arginine derivative that is L-arginine substituted by a phosphono group at N(omega)-position.		2.1710L-arginine derivative;
non-proteinogenic L-alpha-amino acid;
phosphagen;
phosphoamino acid		animal metabolite
depsidomycin
depsidomycin: depsipeptide from Streptomyces lavendofoliae; structure given in first source		2.0110
tyrocidine
Tyrocidine: An antibiotic mixture produced by Bacillus brevis which may be separated into three components, tyrocidines A, B, and C. It is the major constituent (40-60 per cent) of tyrothricin, gramicidin accounting for the remaining 10-20 per cent active material. It is a topical antimicrobial agent, that is very toxic parenterally.. tyrocidine A : A homodetic cyclic decapeptide consisting of D-Phe, L-Pro, L-Phe, D-Phe, L-Asn, L-Gln, L-Tyr, L-Val, L-Orn, and L-Leu residues coupled in sequence and cyclised head-to-tail.. tyrocidine : A mixtue of homodetic cyclic decapeptides produced by the soil bacterium Bacillus brevis.		2.0610homodetic cyclic peptide;
macrocycle;
peptide antibiotic		antibacterial agent;
bacterial metabolite
pyridomycin
pyridomycin: extract of Streptomyces		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		02.5520
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		07.5520
Extensively Drug-Resistant Tuberculosis
Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.		02.1110
Infections, Plasmodium
[description not available]		02.1310
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		07.1310